In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33+ Acute Myeloid Leukemia
Joint Authors
Rousseau, R.
Pizzitola, I.
Biagi, Ettore
Yvon, E.
Valsesia-Wittmann, S.
Lee, D.
Lawson, A.
Brenner, M.
Biondi, A.
Marin, Virna
Finney, H.
Dutour, A.
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-01-05
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Genetic engineering of T cells with chimeric T-cell receptors (CARs) is an attractive strategy to treat malignancies.
It extends the range of antigens for adoptive T-cell immunotherapy, and major mechanisms of tumor escape are bypassed.
With this strategy we redirected immune responses towards the CD33 antigen to target acute myeloid leukemia.
To improve in vivo T-cell persistence, we modified human Epstein Barr Virus-(EBV-) specific cytotoxic T cells with an anti-CD33.CAR.
Genetically modified T cells displayed EBV and HLA-unrestricted CD33 bispecificity in vitro.
In addition, though showing a myeloablative activity, they did not irreversibly impair the clonogenic potential of normal CD34+ hematopoietic progenitors.
Moreover, after intravenous administration into CD33+ human acute myeloid leukemia-bearing NOD-SCID mice, anti-CD33-EBV-specific T cells reached the tumor sites exerting antitumor activity in vivo.
In conclusion, targeting CD33 by CAR-modified EBV-specific T cells may provide additional therapeutic benefit to AML patients as compared to conventional chemotherapy or transplantation regimens alone.
American Psychological Association (APA)
Dutour, A.& Marin, Virna& Pizzitola, I.& Valsesia-Wittmann, S.& Lee, D.& Yvon, E.…[et al.]. 2012. In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33+ Acute Myeloid Leukemia. Advances in Hematology،Vol. 2012, no. 2012, pp.1-10.
https://search.emarefa.net/detail/BIM-490221
Modern Language Association (MLA)
Dutour, A.…[et al.]. In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33+ Acute Myeloid Leukemia. Advances in Hematology No. 2012 (2012), pp.1-10.
https://search.emarefa.net/detail/BIM-490221
American Medical Association (AMA)
Dutour, A.& Marin, Virna& Pizzitola, I.& Valsesia-Wittmann, S.& Lee, D.& Yvon, E.…[et al.]. In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33+ Acute Myeloid Leukemia. Advances in Hematology. 2012. Vol. 2012, no. 2012, pp.1-10.
https://search.emarefa.net/detail/BIM-490221
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-490221